The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A
Open accessAbstract
Individuals with partial HSA21 trisomies and mice with partial MMU16 trisomies containing an extra copy of the DYRK1A gene present various alterations in brain morphogenesis. They present also learning impairments modeling those encountered in Down syndrome. Previous MRI and histological analyses of a transgenic mice generated using a human YAC construct that contains five genes including DYRK1A reveal that DYRK1A is involved, during development, in the control of brain volume and cell density of specific brain regions. Gene dosage correction induces a rescue of the brain volume alterations. DYRK1A is also involved in the control of synaptic plasticity and memory consolidation. Increased gene dosage results in brain morphogenesis defects, low BDNF levels and mnemonic deficits in these mice. Epigallocatechin gallate (EGCG) - a member of a natural polyphenols family, found in great amount in green tea leaves - is a specific and safe DYRK1A inhibitor. We maintained control and transgenic mice overexpressing DYRK1A on two different polyphenol-based diets, from gestation to adulthood. The major features of the transgenic phenotype were rescued in these mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“Bain and colleagues described the properties of 30 inhibitors, tested with 25 different kinases: one of the most specific inhibitors of DYRK1A was epigallocatechin gallate, with an apparent IC50 of 0.33 m M [26].”
InfluentialA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Heldt, S. A., Stanek, L., Chhatwal, J. P., & Ressler, K. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001957 · Cited by 684
An Aneuploid Mouse Strain Carrying Human Chromosome 21 with down Syndrome Phenotypes.
O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M. L., Cooke, S., Sesay, A., Modino, S., Vanes, L., Hernandez, D., et al. (2005) · Science · doi:10.1126/science.1114535 · Cited by 434
Inhibition of GABAASynaptic Responses by Brain-Derived Neurotrophic Factor (BDNF) in Rat Hippocampus
Tanaka, T., Saito, H., & Matsuki, N. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-09-02959.1997 · Cited by 385 · cited 1×
“It has been proposed that it acts as a modulator of GABAergic inhibition [42].”
Plant-Derived Flavanol (−)Epicatechin Enhances Angiogenesis and Retention of Spatial Memory in Mice
van Praag, H., Lucero, M. J., Yeo, G. W., Stecker, K., Heivand, N., Zhao, C., Yip, E., Afanador, M., Schroeter, H., Hammerstone, J., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0914-07.2007 · Cited by 303
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects
Ahn, K.-J., Jeong, H. K., Choi, H.-S., Ryoo, S.-R., Kim, Y. J., Goo, J.-S., Choi, S.-Y., Han, J.-S., Ha, I., & Song, W.-J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.006 · Cited by 220 · cited 2×
“Similar phenotypic alterations have been obtained in mice transgenic for a human BAC [22] carrying only human DYRK1A and with a murine BAC clone carrying only murine Dyrk1a (data not shown).”
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome
Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190
Cited by
Choi, D.-Y., Lee, Y.-J., Hong, J. T., & Lee, H.-J. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.014 · Cited by 305
Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 299
de la Torre, R., de Sola, S., Hernandez, G., Farré, M., Pujol, J., Rodriguez, J., Espadaler, J. M., Langohr, K., Cuenca-Royo, A., Principe, A., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30034-5 · Cited by 289
Self-citationDe la Torre, R., De Sola, S., Pons, M., Duchon, A., de Lagran, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodriguez, J., et al. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300325 · Cited by 286
Self-citationThe role of DYRK1A in neurodegenerative diseases
Wegiel, J., Gong, C., & Hwang, Y. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 284
Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation
Göckler, N., Jofre, G., Papadopoulos, C., Soppa, U., Tejedor, F. J., & Becker, W. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07346.x · Cited by 278
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T., Onogi, H., Shibuya, H., et al. (2010) · Nature Communications · doi:10.1038/ncomms1090 · Cited by 276
Down syndrome: the brain in trisomic mode
Dierssen, M. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3314 · Cited by 274
Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00063-6 · Cited by 264
Mégarbané, A., Ravel, A., Mircher, C., Sturtz, F., Grattau, Y., Rethoré, M.-O., Delabar, J.-M., & Mobley, W. C. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181b2e34c · Cited by 260
Self-citationNeurological phenotypes for Down syndrome across the life span
Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225
“In a study utilizing a polyphenol diet, the major features of the transgenic phenotype were rescued (Guedj et al., 2009).”
BackgroundTrisomy 21 and early brain development
Haydar, T. F., & Reeves, R. H. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.001 · Cited by 200
“While encouraging results demonstrate that the DYRK1A inhibitor, epigallocatechin gallate (a phenol found in green tea), may improve cognitive function in trisomic animals [112], it remains to be seen whether this therapeutic approach will correct any DYRK1A-associated developmental changes.”
ResultDuchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
Hibaoui, Y., Grad, I., Letourneau, A., Sailani, M. R., Dahoun, S., Santoni, F. A., Gimelli, S., Guipponi, M., Pelte, M. F., Béna, F., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302848 · Cited by 170
“…assembly (Ciani & Salinas, 2005; Breunig et al, 2007; Ables et al, 2011) and could explain at least in part, the defects in dendritic development due to DYRK1A overexpression in the present study and recent reports (Guedj et al, 2009; Tejedor & H€ammerle, 2011; Martinez de Lagran et al, 2012).”
BackgroundResultHämmerle, B., Ulin, E., Guimera, J., Becker, W., Guillemot, F., & Tejedor, F. J. (2011) · Development · doi:10.1242/dev.066167 · Cited by 137
Fragile X Syndrome: from molecular pathology to therapy
Maurin, T., Zongaro, S., & Bardoni, B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.006 · Cited by 113
García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104
Self-citationAtas-Ozcan, H., Brault, V., Duchon, A., & Herault, Y. (2021) · Genes · doi:10.3390/genes12111833 · Cited by 78
Altafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75
Therapeutic approaches in the improvement of cognitive performance in Down syndrome
de la Torre, R., & Dierssen, M. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00001-7 · Cited by 53
Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43
Synaptic Pathology of Down Syndrome
Garner, C. C., & Wetmore, D. Z. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_20 · Cited by 33
DYRK1A BAC Transgenic Mouse: A New Model of Thyroid Dysgenesis in Down Syndrome
Kariyawasam, D., Rachdi, L., Carré, A., Martin, M., Houlier, M., Janel, N., Delabar, J.-M., Scharfmann, R., & Polak, M. (2015) · Endocrinology · doi:10.1210/en.2014-1329 · Cited by 30
Self-citationScala, I., Valenti, D., Scotto D’Aniello, V., Marino, M., Riccio, M. P., Bravaccio, C., Vacca, R. A., & Strisciuglio, P. (2021) · Antioxidants · doi:10.3390/antiox10030469 · Cited by 25
“EGCG is also a specific and safe inhibitor of DYRK1A [30] and it was found to improve brain defects induced by DYRK1A overexpression [31,32].”
Background
Metadata
- Authors
- Guedj, F., Sébrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E., Gillet, B., Arbones, M., & Delabar, J. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-02-26
- Volume
- 4
- Issue
- 2
- Pages
- e4606
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2094573922
- Cited by
- 216
- References
- 11
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.